Promore Pharma looks to expand PXL01 indications
Promore Pharma (Nasdaq: PROMO), a Swedish developer of therapeutic peptides, plans to expand the indications of its lead compound, the anti-adhesion and anti-scarring agent PXL01, to explore the feasibility of using the compound for the prevention of dermal scarring.
Formerly known as Pergamum, Promore shares rose 8.47% to 16.00 Swedish kronor in morning trading today on the Stockholm Exchange.
PXL01 is currently in clinical Phase III development for the prevention of post-surgical adhesions after tendon repair surgery in the hand. Promore has now planned for a clinical Phase I/II study in the field of dermal scarring. The study will be performed in Sweden and co-ordinated by Fredrik Huss, Associate Professor in Plastic Surgery at Uppsala University.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze